Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors

M. C. Foncuberta, P. J. Cagnoni, C. H. Brandts, R. Mandanas, K. Fields, H. G. Derigs, Elizabeth Cecile Reed, S. T. Sonis, J. Fay, F. LeVeque, P. Pouillart, H. Schrezenmeier, R. Emmons, E. Thiel

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Transforming growth factor (TGF)-β3 has been hypothesized to prevent or alleviate oral mucositis (OM) in cancer patients receiving high-dose chemotherapy (CT). Two double-blind, placebo-controlled, multicenter, phase II studies of TGF-β3 were initiated in the United States, Europe, and Argentina in patients with lymphomas or solid tumors who were receiving highly stomatotoxic CT regimens. Patients were to apply 10-mL mouthwash applications of TGF-β3 (25 μg/mL) or placebo four times daily (or twice daily) 1 day before and all days during CT. The patients were subsequently evaluated for OM incidence, severity, and duration using National Institute of Cancer Common Toxicity Criteria (NCI-CTC) criteria and an objective scoring system (1). After the start of the trials, negative results from new preclinical studies suggesting suboptimal formulation and/or dosing led to an interim analysis of the ongoing clinical trials. One hundred fifty-two patients from the combined studies were included in the interim analysis, with 116 patients on the TGF-β3 four times daily and placebo arms. Most (72%) patients had breast cancer, 22% had lymphomas, and 6% had other solid tumors. Although 98% (149 of 152) of patients experienced adverse events, only 14% (22 of 152) experienced events that were judged as possibly or probably related to the study drug (primarily gastrointestinal symptoms). No clinically relevant differences were seen between the treatment and placebo arms regarding safety, nor was there evidence for systemic absorption of TGF-β3. Finally, there was no advantage of TGF-β3 treatment regarding the incidence (TGF-β3 four times daily versus placebo [46% versus 47%]), onset, or duration of NCI-CTC grade 3 or 4 OM. For this dose, formulation, regimen, and patient population, TGF-β3 was not effective in the prevention or alleviation of CT-induced OM.

Original languageEnglish (US)
Pages (from-to)384-388
Number of pages5
JournalJournal of Immunotherapy
Volume24
Issue number4
DOIs
StatePublished - Jan 1 2001

Fingerprint

Stomatitis
Transforming Growth Factors
Lymphoma
Drug Therapy
Neoplasms
Placebos
Mouthwashes
Gastrointestinal Agents
National Cancer Institute (U.S.)
Population Growth
Argentina
Incidence
Clinical Trials
Breast Neoplasms
Safety

Keywords

  • High-dose chemotherapy
  • Objective scoring system for oral mucositis
  • Oral mucositis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors. / Foncuberta, M. C.; Cagnoni, P. J.; Brandts, C. H.; Mandanas, R.; Fields, K.; Derigs, H. G.; Reed, Elizabeth Cecile; Sonis, S. T.; Fay, J.; LeVeque, F.; Pouillart, P.; Schrezenmeier, H.; Emmons, R.; Thiel, E.

In: Journal of Immunotherapy, Vol. 24, No. 4, 01.01.2001, p. 384-388.

Research output: Contribution to journalArticle

Foncuberta, MC, Cagnoni, PJ, Brandts, CH, Mandanas, R, Fields, K, Derigs, HG, Reed, EC, Sonis, ST, Fay, J, LeVeque, F, Pouillart, P, Schrezenmeier, H, Emmons, R & Thiel, E 2001, 'Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors', Journal of Immunotherapy, vol. 24, no. 4, pp. 384-388. https://doi.org/10.1097/00002371-200107000-00014
Foncuberta, M. C. ; Cagnoni, P. J. ; Brandts, C. H. ; Mandanas, R. ; Fields, K. ; Derigs, H. G. ; Reed, Elizabeth Cecile ; Sonis, S. T. ; Fay, J. ; LeVeque, F. ; Pouillart, P. ; Schrezenmeier, H. ; Emmons, R. ; Thiel, E. / Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors. In: Journal of Immunotherapy. 2001 ; Vol. 24, No. 4. pp. 384-388.
@article{a2144916f8e44c67bbfd81a1aaaa6be5,
title = "Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors",
abstract = "Transforming growth factor (TGF)-β3 has been hypothesized to prevent or alleviate oral mucositis (OM) in cancer patients receiving high-dose chemotherapy (CT). Two double-blind, placebo-controlled, multicenter, phase II studies of TGF-β3 were initiated in the United States, Europe, and Argentina in patients with lymphomas or solid tumors who were receiving highly stomatotoxic CT regimens. Patients were to apply 10-mL mouthwash applications of TGF-β3 (25 μg/mL) or placebo four times daily (or twice daily) 1 day before and all days during CT. The patients were subsequently evaluated for OM incidence, severity, and duration using National Institute of Cancer Common Toxicity Criteria (NCI-CTC) criteria and an objective scoring system (1). After the start of the trials, negative results from new preclinical studies suggesting suboptimal formulation and/or dosing led to an interim analysis of the ongoing clinical trials. One hundred fifty-two patients from the combined studies were included in the interim analysis, with 116 patients on the TGF-β3 four times daily and placebo arms. Most (72{\%}) patients had breast cancer, 22{\%} had lymphomas, and 6{\%} had other solid tumors. Although 98{\%} (149 of 152) of patients experienced adverse events, only 14{\%} (22 of 152) experienced events that were judged as possibly or probably related to the study drug (primarily gastrointestinal symptoms). No clinically relevant differences were seen between the treatment and placebo arms regarding safety, nor was there evidence for systemic absorption of TGF-β3. Finally, there was no advantage of TGF-β3 treatment regarding the incidence (TGF-β3 four times daily versus placebo [46{\%} versus 47{\%}]), onset, or duration of NCI-CTC grade 3 or 4 OM. For this dose, formulation, regimen, and patient population, TGF-β3 was not effective in the prevention or alleviation of CT-induced OM.",
keywords = "High-dose chemotherapy, Objective scoring system for oral mucositis, Oral mucositis",
author = "Foncuberta, {M. C.} and Cagnoni, {P. J.} and Brandts, {C. H.} and R. Mandanas and K. Fields and Derigs, {H. G.} and Reed, {Elizabeth Cecile} and Sonis, {S. T.} and J. Fay and F. LeVeque and P. Pouillart and H. Schrezenmeier and R. Emmons and E. Thiel",
year = "2001",
month = "1",
day = "1",
doi = "10.1097/00002371-200107000-00014",
language = "English (US)",
volume = "24",
pages = "384--388",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Topical Transforming Growth Factor-β3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors

AU - Foncuberta, M. C.

AU - Cagnoni, P. J.

AU - Brandts, C. H.

AU - Mandanas, R.

AU - Fields, K.

AU - Derigs, H. G.

AU - Reed, Elizabeth Cecile

AU - Sonis, S. T.

AU - Fay, J.

AU - LeVeque, F.

AU - Pouillart, P.

AU - Schrezenmeier, H.

AU - Emmons, R.

AU - Thiel, E.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Transforming growth factor (TGF)-β3 has been hypothesized to prevent or alleviate oral mucositis (OM) in cancer patients receiving high-dose chemotherapy (CT). Two double-blind, placebo-controlled, multicenter, phase II studies of TGF-β3 were initiated in the United States, Europe, and Argentina in patients with lymphomas or solid tumors who were receiving highly stomatotoxic CT regimens. Patients were to apply 10-mL mouthwash applications of TGF-β3 (25 μg/mL) or placebo four times daily (or twice daily) 1 day before and all days during CT. The patients were subsequently evaluated for OM incidence, severity, and duration using National Institute of Cancer Common Toxicity Criteria (NCI-CTC) criteria and an objective scoring system (1). After the start of the trials, negative results from new preclinical studies suggesting suboptimal formulation and/or dosing led to an interim analysis of the ongoing clinical trials. One hundred fifty-two patients from the combined studies were included in the interim analysis, with 116 patients on the TGF-β3 four times daily and placebo arms. Most (72%) patients had breast cancer, 22% had lymphomas, and 6% had other solid tumors. Although 98% (149 of 152) of patients experienced adverse events, only 14% (22 of 152) experienced events that were judged as possibly or probably related to the study drug (primarily gastrointestinal symptoms). No clinically relevant differences were seen between the treatment and placebo arms regarding safety, nor was there evidence for systemic absorption of TGF-β3. Finally, there was no advantage of TGF-β3 treatment regarding the incidence (TGF-β3 four times daily versus placebo [46% versus 47%]), onset, or duration of NCI-CTC grade 3 or 4 OM. For this dose, formulation, regimen, and patient population, TGF-β3 was not effective in the prevention or alleviation of CT-induced OM.

AB - Transforming growth factor (TGF)-β3 has been hypothesized to prevent or alleviate oral mucositis (OM) in cancer patients receiving high-dose chemotherapy (CT). Two double-blind, placebo-controlled, multicenter, phase II studies of TGF-β3 were initiated in the United States, Europe, and Argentina in patients with lymphomas or solid tumors who were receiving highly stomatotoxic CT regimens. Patients were to apply 10-mL mouthwash applications of TGF-β3 (25 μg/mL) or placebo four times daily (or twice daily) 1 day before and all days during CT. The patients were subsequently evaluated for OM incidence, severity, and duration using National Institute of Cancer Common Toxicity Criteria (NCI-CTC) criteria and an objective scoring system (1). After the start of the trials, negative results from new preclinical studies suggesting suboptimal formulation and/or dosing led to an interim analysis of the ongoing clinical trials. One hundred fifty-two patients from the combined studies were included in the interim analysis, with 116 patients on the TGF-β3 four times daily and placebo arms. Most (72%) patients had breast cancer, 22% had lymphomas, and 6% had other solid tumors. Although 98% (149 of 152) of patients experienced adverse events, only 14% (22 of 152) experienced events that were judged as possibly or probably related to the study drug (primarily gastrointestinal symptoms). No clinically relevant differences were seen between the treatment and placebo arms regarding safety, nor was there evidence for systemic absorption of TGF-β3. Finally, there was no advantage of TGF-β3 treatment regarding the incidence (TGF-β3 four times daily versus placebo [46% versus 47%]), onset, or duration of NCI-CTC grade 3 or 4 OM. For this dose, formulation, regimen, and patient population, TGF-β3 was not effective in the prevention or alleviation of CT-induced OM.

KW - High-dose chemotherapy

KW - Objective scoring system for oral mucositis

KW - Oral mucositis

UR - http://www.scopus.com/inward/record.url?scp=17944368738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944368738&partnerID=8YFLogxK

U2 - 10.1097/00002371-200107000-00014

DO - 10.1097/00002371-200107000-00014

M3 - Article

VL - 24

SP - 384

EP - 388

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 4

ER -